Anethole inhibits the proliferation of human prostate cancer cells via induction of cell cycle arrest and apoptosis

Anti-Cancer Agents in Medicinal Chemistry

Volumn 18, Issue 2, 2018, Pages 216-236

  Elkady, Ayman I ^a,b  

^a Alexandria University Faculty Of Science   (Egypt)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Anethole; Apoptosis; Cell cycle; DNA damage; Oxidative stress; Prostate cancer

Indexed keywords

ANETHOLE; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; PROTEIN P21; PROTEIN P27; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; CANCER THERAPY; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; COMET ASSAY; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; ENZYME ACTIVITY; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MTT ASSAY; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 85032000583     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520617666170725165717     Document Type: Article

References (100)

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin., 2015, 65, 5-29.
2. Schroder, F.H. Progress in understanding androgen-independent prostate cancer (AIPC): A review of potential endocrine-mediated mechanisms, Eur. Urol., 2008, 53, 1129-1137.
3. Devlin, H.L.; Mudryj, M. Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett., 2009, 274, 177-186.
4. Attard, G.; Parker, C.; Eeles, R.A.; Schroder, F.; Tomlins, S.A.; Tannock, I.; Drake, C.G.; de Bono, J.S. Prostate cancer. Lancet, 2016, 387(10013), 70-82.
5. Chen, F.Z.; Zhao, X.K. Prostate Cancer: Current Treatment and Prevention Strategies. Iran Red Crescent Med J. 2013, 15, 279-284.
6. Bahnson R. Androgen deprivation therapy for prostate cancer. J Urol., 2007, 178, 1148.
7. Wong, R.S.Y. “Apoptosis in cancer: frompathogenesis to treatment,” J. Exp. Clin. Cancer Res., 2011, 30(1), 87.
8. Huang, X.; Zhang, X.; Farahvash, B.; Olumi, A.F. Novel targeted pro-apoptotic agents for the treatment of prostate cancer. J. Urol., 2007, 178(5), 1846-1854.
9. Safarzadeh, E.; Sandoghchian, S.S.; Baradaran, B. Herbal Medicine as inducers of apoptosis in cancer treatment. Adv. Pharm. Bull., 2014, 4(Suppl 1), 421-427.
10. Diaaz-Maroto, M.C.; Pearez-Coello, M.S.; Esteban, J.; Sanz, J. Comparison of the volatile composition of wild fennel samples (Foeniculum vulgare Mill.) from Central Spain. J. Agric. Food Chem., 2006, 54, 6814-6818.
11. Newberne, P.; Smith, R.L.; Doull, J.; Goodman, J.I.; Munro, I.C.; Portoghese, P.S.; Wagner, B.M.; Weil, C.S.; Woods, L.A.; Adams, T.B.; Lucas, C.D.; Ford, R.A. The FEMA GRAS assessment of trans-anethole used as a flavoring substance. Food Chem. Toxicol., 1999, 37, 789-811.
12. Freire, R.S.; Morais, S.M.; Catunda-Junior, F.E.A.; Pinheiro, D.C.N. Synthesis and antioxidant, anti-inflammatory and gastroprotector activities of anethole and related compounds. Bioorg. Med. Chem., 2005, 13, 4353-4358.
13. Chen, C.H.; deGraffenried, L.A. Anethole suppressed cell survival and induced apoptosis in human breast cancer cells independent of estrogen receptor status. Phytomedicine, 2012, 19, 763-767.
14. Choo, E.J.; Rhee, Y.H.; Jeong, S.J.; Lee, H.J.; Kim, H.S.; Ko, H.S.; Kim, J.H.; Kwon, T.R.; Jung, J.H.; Kim, J.H.; Lee, H.J.; Lee, E.O.; Kim, D.K.; Chen, C.Y.; Kim, S.H. Anethole exerts antimetatstaic activity via inhibition of matrix metalloproteinase 2/9 and AKT/mitogen-activated kinase/nuclear factor kappa B signaling pathways. Biol. Pharm. Bull., 2011, 34(1), 41-46.
15. Al-Harbi, M.M.; Qureshi, S.; Raza, M.; Ahmed, M.M.; Giangreco, A.B.; Shah, A.H. Influence of anethole treatment on the tumour induced by Ehrlich ascites carcinoma cells in paw of Swiss albino mice. Eur. J. Cancer Prev., 1995, 4(4), 307-318.
16. Reddy, B., Rao, C., Rivenson, A., Kelloff, G., 1993. Chemoprevention of colon carcinogenesis by organosulfur compounds. Cancer Res., 1993, 53, 3493-3498.
17. Lubet, R.A.; Steele, V.E.; Eto, I.; Juliana, M.M.; Kelloff, G.J. Chemopreventive efficacy of anethole trithione, N-acetyl-l-cysteine, miconazole and phenethylisothiocyanate in the DMBA-induced rat mammary cancer model. Int. J. Cancer,1997, 72, 95-101.
18. Lam, S.; MacAulay, C.; Le Riche, J.C.; Dyachkova, Y.; Coldman, A.; Guillaud, M.; Hawk, E.; Christen, M.O.; Gazdar, A.F. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J. Natl. Cancer Inst. 2002, 94(13), 1001-1009.
19. Pal, S.; Bhattacharjee, A.; Ali, A.; Mandal, N.C.; Mandal, S.C.; Pal, M. Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism. J. Inflamm. (Lond)., 2014, 11, 23.
20. Okada, F. Inflammation-related carcinogenesis: current findings in epidemiological trends, causes and mechanisms. Yonago Acta Med., 2014, 57(2), 65-72.
21. Porta, C.; Larghi, P.; Rimoldi, M.; Totaro, M.G.; Allavena, P.; Mantovani, A.; Sica, A. Cellular and molecular pathways linking inflammation and cancer. Immunobiology, 2009, 214(9-10), 761-77.
22. Sethi, G.; Sung, B.; Aggarwal, B.B. Nuclear factor-κB activation: from bench to bedside. Exp. Bio. Med., 2008, 233(1), 21-31.
23. Chainy, G.B.; Manna, S.K.; Chaturvedi, M.M.; Aggarwal, B.B. Anethole blocks both early and late cellular responses transduced by tumor necrosis factor: Effect on NF-kappaB, AP-1, JNK, MAPKK and apoptosis. Oncogene, 2000, 19(25), 2943-2950.
24. Domiciano, T.P.; Dalalio, M.M.; Silva, E.L.; Ritter, A.M.; Estevao-Silva, C.F.; Ramos, F.S.; Caparroz-Assef, S.M.; Cuman, R.K.; Bersani-Amado, C.A. Inhibitory effect of anethole in nonimmune acute inflammation. Naunyn Schmiedebergs Arch. Pharmacol., 2013, 386(4), 331-338.
25. Moradi J.; Abbasipour, F.; Zaringhalam, J.; Maleki, B.; Ziaee, N.; Khodadoustan, A.; Janahmadi, M. Anethole, a medicinal plant compound, decreases the production of pro-inflammatory TNF-α and IL-1β in a rat model of LPS-Induced periodontitis. Iran J. Pharm. Res., 2014, 13(4), 1319-25.
26. Elkady, A.I.; Hussein, R.A.; El-Assouli, Sufian, M. Mechanism of Action of Nigella sativa on human colon cancer cells: The suppression of AP-1 and NF-κB transcription factors and the induction of cytoprotective genes. Asian Pac. J. Cancer Prev., 2015, 16(17), 7943-7957.
27. Elkadyk A.I. Crude extract of Nigella sativa inhibits proliferation and induces apoptosis in human cervical carcinoma HeLa cells. A. J. Biotech., 2012, 11(64), 12710-12720.
28. Elkady, A.I. Crude alkaloid extract of Rhazya stricta inhibits cell growth and sensitizes human lung cancer cells to cisplatin through induction of apoptosis. Gene. Mol. Bio., 2013, 36(1), 12-21.
29. Elkady, A.I.; Hussein, R.A.; Abu-Zinadah, O.A. Effects of crude extracts from medicinal herbs Rhazya stricta and Zingiber officinale on growth and proliferation of human brain cancer cell line in vitro. Biomed. Res. Int., 2014, 2014, 260210, doi: 10.1155/2014/260210.
30. El-Merahbi R, Liu, Y.N.; Eid, A.; Daoud, G.; Hosry, L.; Monzer, A.; Mouhieddine, T.H.; Hamade, A.; Najjar, F.; Abou-Kheir, W. Berberis libanotica Ehrenb extract shows anti-neoplastic effects on prostate cancer stem/progenitor cells. PLoS One, 2014, 9(11), e112453.
31. Zhang, L., Jiao, M., Li, L., Wu, D., Wu, K.; Li, X.; Zhu, G.; Dang, Q.; Wang, X.; Hsieh, J.T.; He, D. Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties. J. Cancer Res. Clin. Oncol., 2012, 138(4), 675-686.
32. Wang, L.; Huang, X.; Zheng, X.; Wang, X.; Li, S.; Zhang, L.; Yang, Z.; Xia, Z. Enrichment of prostate cancer stem-like cells from human prostate cancer cell lines by culture in serum-free medium and chemoradiotherapy. Int. J. Biol. Sci., 2013, 9(5), 472-479.
33. Antosiewicz, J.; Ziolkowski, W.; Kar, S.; Powolny, A.A.; Singh, S.V. Role of reactive oxygen intermediates in cellular responses to dietary cancer chemopreventive agents. Planta. Med., 2008, 74(13), 1570-1579.
34. Susin, S.A.; Lorenzo, H.K.; Zamzami, N.; Marzo, I.; Snow, B.E.; Brothers, G.M.; Mangion, J.; Jacotot, E.; Costantini, P.; Loeffler, M.; Larochette, N.; Goodlett, D.R.; Aebersold, R.; Siderovski, D.P.; Penninger, J.M.; Kroemer, G. Molecular characterization of mitochondrial apoptosis-inducing factors. Nature, 1999, 397, 441-446.
35. Collins, J.A.; Schandi, C.A.; Young, K.K.; Vesely, J.; Willingham, M.C. Major DNA fragmentation is a late event in apoptosis. J. Histochem. Cytochem., 1997, 45(7), 923-934.
36. Hainaut, P.; Wiman, K.G. 30 years and a long way into p53 research. Lancet Oncol., 2009, 10, 913-919.
37. Isaacs, W.B.; Carter, B.S.; Ewing, C.M. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res., 1991, 51, 4716-4720.
38. Drobnjak, M.; Osman, I.; Scher, H.I.; Fazzari, M.; Cordon-Cardo, C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin. Cancer Res., 2000, 6, 1891-1895.
39. Vermeulen, K.; Van Bockstaele, D.R.; Berneman, Z.N. The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif., 2003, 36, 131-149.
40. Zeng, W.; Sun, H.; Meng, F.; Liu, Z.; Xiong, J.; Zhou, S.; Li, F.; Hu, J, Hu, Z.; Liu, Z. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer. Int. J. Clin. Exp. Pathol., 2015, 8, 1878-1888.
41. Nguyen, D.P.; Li, J.; Yadav, S.S.; Tewari, A.K. Recent insights into NF-κB signaling pathways and the link between inflammation and prostate cancer. BJU Int., 2014, 114(2), 168-176.
42. Jain, G.; Cronauer, M.V.; Schrader, M.; Moller, P.; Marienfeld, R.B. NF-κB signaling in prostate cancer: a promising therapeutic target? World. J. Urol., 2012, 30(3), 303-310.
43. Deveraux, Q.L.; Reed, J.C. IAP family proteins-suppressors of apoptosis. Genes Dev., 1999, 13(3), 239-252.
44. Kang, P.; Kim, K.Y.; Lee, H.S.; Min, S.S.; Seol, G.H. Antiinflammatory effects of anethole in lipopolysaccharide-induced acute lung injury in mice. Life Sciences, 2013, 93, 955-961.
45. Jana, S.; Patra, K.; Mukherjee, G.; Bhattacharjee, S.; Mandal, D.P. Antitumor potential of anethole singly and in combination with cyclophosphamide in murine Sarcoma-180 transplantable tumor model. RSC Adv., 2015, 5, 56549-56559.
46. Tai, S.; Sun, Y.; Squires, J.M.; Zhang, H.; Oh, W.K.; Liang, C.Z.; Huang, J. PC-3 is a cell line characteristic of prostatic small cell carcinoma. Prostate, 2011, 71(15), 1668-1679.
47. Greenlee, RT.; Murray, T.; Bolden, S.; Wingo, P.A. Cancer statistics, 2000. CA Cancer J Clin., 2000, 50(1), 7-33.
48. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell, 2011, 144(5), 646-674.
49. Ojo, D.; Lin, X.; Wong, N.; Gu, Y.; Tang, D. Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer. Cancers (Basel). 2015, 7(4), 2290-308.
50. Khan, N.; Afaq, F.; Mukhtar, H. Apoptosis by dietary factors: The suicide solution for delaying cancer growth. Carcinogenesis, 2007, 28, 233-239.
51. Melet, A.; Song, K.; Bucur, O.; Jagani, Z.; Grassian A.R.; Khosravi-Far, R. Apoptotic Pathways in Tumor Progression and Therapy. In Programmed Cell Death in Cancer Progression and Therapy, White ed.; Khosravi-Far.; Roya.; White.; Eileen.; Springer, Germany, 2008; pp. 47.
52. Schultz, D.R.; Harrington, WJ. Jr. Apoptosis: Programmed cell death at a molecular level. Sem. Arth. Rheum, 2003, 32(6), 345-369.
53. Fruehauf, J.P.; Meyskens, F.L.Jr. Reactive oxygen species: A breath of life or death? Clin Cancer Res., 2007, 13(3), 789-794.
54. Engel, R.H.; Evens, A.M. Oxidative stress and apoptosis: A new treatment paradigm in cancer. Front Biosci, 2006, 11, 300-312.
55. Pelicano, H.; Carney, D.; Huang, P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat., 2004, 7, 97-110.
56. Nishikawa, Y.; Okuzaki, D.; Fukushima, K.; Mukai, S.; Ohno, S.; Ozaki, Y.; Yabuta, N.; Nojima, H. Withaferin A Induces Cell Death Selectively in Androgen-Independent Prostate Cancer Cells but Not in Normal Fibroblast Cells. PLoS One, 2015, 10(7), e0134137.
57. Zhang, X.; Chen, M.; Zou, P.; Kanchana, K.; Weng, Q.; Chen, W.; Zhong, P.; Ji, J.; Zhou, H.; He, L.; Liang, G. Curcumin analog WZ35 induced cell death via ROS-dependent ER stress and G2/M cell cycle arrest in human prostate cancer cells. BMC Cancer, 2015, 15, 866.
58. Kim, S.H.; Kim, K.Y.; Yu, S.N.; Seo, Y.K.; Chun, S.S.; Yu, H.S.; Ahn, S.C..Silibinin induces mitochondrial NOX4-mediated endoplasmic reticulum stress response and its subsequent apoptosis. BMC Cancer, 2016, 16, 452.
59. Trachootham, D.; Alexandre, J.; Huang, P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov., 2009, 8(7), 579-591.
60. Česen, M.H.; Pegan, K.; Spes, A.; Turk, B. Lysosomal pathways to cell death and their therapeutic applications. Exp. Cell Res., 2012, 318(11), 1245-1251.
61. Mijatovic, T.; Mathieu V.; Gaussin, J.F.; De Neve, N.; Ribaucour, F.; Van Quaquebeke, E.; Dumont, P.; Darro, F.; Kiss, R. Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers. Neoplasia, 2006, 8, 402-412.
62. Repnik, U.; Turk, B. Lysosomal-mitochondrial cross-talk during cell death. Mitochondrion., 2010, 10(6), 662-669.
63. Chan, S.L.; Yu, V.C. Proteins of the bcl-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities. Clin. Exp. Pharmacol. Physiol., 2004, 31(3), 119-128.
64. Hughes, C.; Murphy, A.; Martin, C.; Sheils, O, O'Leary, J. Molecular pathology of prostate cancer. J Clin Pathol., 2005, 58, 673-684.
65. Catz, S.D.; Johnson, J.L. BCL-2 in prostate cancer: A minireview. Apoptosis, 2003, 8, 29-37.
66. Sternberg, C.N.; Dumez, H.; Van Poppel, H.; Skoneczna, I.; Sella, A.; Daugaard, G.; Gil, T.; Graham, J.; Carpentier, P.; Calabro, F.; Collette, L.; Lacombe, D. EORTC Genitourinary Tract Cancer Group. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): An EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann. Oncol., 2009, 20(7), 1264-1269.
67. Kelly, G.L.; Andreas Strasser, A. The essential role of evasion from cell death in cancer. Adv Cancer Res., 2011, 111, 39-96.
68. Fulda, S.; Debatin, K.M. Targeting apoptosis pathways in cancer therapy. Curr. Cancer Drug Targets, 2004, 4, 569-76.
69. Norbury, C.J.; Zhivotovsky, B. DNA damage-induced apoptosis. Oncogene, 2004, 23, 2797-2808.
70. Roos, W.P.; Kaina, B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett., 2013, 332(2), 237-248.
71. Yasuhara, S.; Zhu, Y.; Matsui, T.; Tipirneni, N.; Yasuhara, Y.; Kaneki, M.; Rosenzwe, A.; Martyn, J.A. Comparison of comet assay, electron microscopy, and flow cytometry for detection of apoptosis. J. Histochem. Cytochem., 2003, 51(7), 873-885.
72. Chakraborty, S.; Kundu, T.; Dey, S.; Bhattacharya, R.K.; Siddiqi, M.; Roy, M. Tea-induced apoptosis in human leukemia K562 cells as assessed by comet formation. Asian Pac. J. Cancer Prev., 2006, 7(2), 201-207.
73. Molinari, M. Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif., 2000, 33, 261-274.
74. Singh, R.P.; Agarwal, R. Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocrine-Related Can., 2006, 13, 751-778.
75. Noel, E.E.; Yeste-Velasco, M.; Mao, X.; Perry, J.; Kudahetti, S.C.; Li, N.F.; Sharp, S.; Chaplin, T.; Xue, L.; McIntyre, A.; Shan, L.; Powles, T.; Oliver, R.T.; Young, B.D.; Shipley, J.; Berney, D.M.; Joel, S.P.; Lu, Y.J. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am. J. Pathol., 2010, 176, 2607-2615.
76. Ding, Z.; Wu, ClJ.; Chu, G.C. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature, 2011, 470(7333), 269-273.
77. Hall, M.; Peters, G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res., 1996, 68, 67-108.
78. Gulappa, T.; Reddy, R.S.; Suman, S.; Nyakeriga, A.M.; Damodaran, C. Molecular interplay between cdk4 and p21 dictates G0/G1 cell cycle arrest in prostate cancer cells. Cancer Lett., 2013, 337(2), 177-183.
79. Tsihlias, J.; Kapusta, L.R.; DeBoer, G.; Morava-Protzner, I.; Zbieranowski, I.; Bhattacharya, N.; Catzavelos, G.C.; Klotz, L.H.; Slingerland, J.M. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res., 1998, 58(3), 542-548.
80. Sanchez-Gonzalez, C.; Ciudad, C.J.; Izquierdo-Pulido, M.; Noe, V. Urolithin A causes p21 up-regulation in prostate cancer cells. Eur J Nutr., 2016, 55(3), 1099-1112.
81. Burgess, A.; Wigan, M.; Giles, N.; Depinto, W.; Gillespie, P.; Stevens, F.; Gabrielli, B. Inhibition of S/G2 phase CDK4 reduces mitotic fidelity. J. Biol Chem., 2006, 281(15), 9987-9995.
82. Guo, Y.X.; Lin, Z.M.; Wang, M.J.; Dong, Y.W.; Niu, H.M.; Young, C.Y.; Lou, H.X.; Yuan, H.Q. Jungermannenone A and B induce ROS-and cell cycle-dependent apoptosis in prostate cancer cells in vitro. Acta Pharmacol. Sin., 2016, 37(6), 814-824.
83. Qiu, P.; Dong, P.; Guan, H.; Li, S.; Ho, C.T.; Pan, M.H.; McClements, D.J.; Xiao, H. Inhibitory effects of 5-hydroxy polymethoxyflavones on colon cancer cells. Mol. Nutr. Food Res., 2010, Suppl 2, S244-S252, doi: 10.1002/mnfr.200900605.w
84. Gonzalez-Sarrias, A.; Ma, H.; Edmonds, M.E.; Seeram, N.P. Maple polyphenols, ginnalins A-C, induce S-and G2/M-cell cycle arrest in colon and breast cancer cells mediated by decreasing cyclins A and D1 levels. Food Chem., 2013, 136, 636-642.
85. Bretones, G.; Delgado, M.D.; Leon, J. Myc and cell cycle control. Biochim. Biophys. Acta, 2015, 1849(5), 506-516.
86. Hahm, E.R.; Singh, K.B.; Singh, S.V. c-Myc is a novel target of cell cycle arrest by honokiol in prostate cancer cells. Cell Cycle, 2016, 15(17), 2309-2320.
87. Robinson, D.; Van Allen, E.M.; Wu, Y.M. Integrative clinical genomics of advanced prostate cancer. Cell, 2015, 161, 1215-1228.
88. Koh, C.M.; Bieberich, C.J.; Dang, C.V.; Nelson, W.G.; Yegnasubramanian, S.; De Marzo, A.M. MYC and Prostate Cancer. Genes Cancer, 2010, 1, 617-628.
89. Sato, K.; Qian, J.; Slezak, J.M.; Lieber, M.M.; Bostwick, D.G.; Bergstralh, E.J.; Jenkins, R.B. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J. Natl. Cancer Inst., 1999, 91(18), 1574-1580.
90. Hawksworth, D.; Ravindranath, L.; Chen, Y.; Furusato, B.; Sesterhenn, I.A.; McLeod, D.G.; Srivastava, S.; Petrovics, G. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Pros. Can. Prost. Dis., 2010, 13, 311-315.
91. Lessard, L.; Mes-Masson, A.M.; Lamarre, L.; Wall, L.; Lattouf, J.B.; Saad, F. NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int., 2003, 91, 417-420.
92. Shukla, S.; MacLennan, G.T.; Fu, P.; Patel, J.; Marengo, S.R.; Resnick, M.I. Gupta, S. Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia, 2004, 6, 390-400.
93. Huang, S.; Pettaway, C.A.; Uehara, H.; Bucana, C.D.; Fidler, I.J. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene, 2001, 20, 4188-4197.
94. Chen, C.D.; Sawyers, C.L. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol. Cell Biol., 2002, 22, 2862-2870.
95. Wang, H.Q.; Li, D.L., Lu, Y.J.; Cui, X.X.; Zhou, X.F.; Lin, W.P.; Conney, A.H.; Zhang, K.; Du, Z.Y.; Zheng, X. Anticancer activity of Acanthopanax trifoliatus (L) Merr extracts is associated with Inhibition of NF-kB activity and decreased Erk1/2 and Akt Phosphorylation. Asian Pac. J. Cancer Prev., 2014, 15(21), 9341-9346.
96. Shukla, S.; Kanwal, R.; Shankar, E.; Datt, M.; Chance, M.R.; Fu, P.; MacLennan, G.T.; Gupta, S. Apigenin blocks IKKα activation and suppresses prostate cancer progression. Oncotarget, 2015, 6 (31), 31216-31232.
97. Chiu, C.T.; Chen, J.H.; Chou, F.P.; Lin, H.H. Lin Hibiscus sabdariffa Leaf Extract Inhibits Human Prostate Cancer Cell Invasion via Down-Regulation of Akt/NF-κB/MMP-9 Pathway. Nutrients, 2015, 7, 5065-5087.
98. Shariat, S.F.; Lotan, Y.; Saboorian, H.; Khoddami, S.M.; Roehrborn, C.G.; Slawin, K.M.; Ashfaq, R. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer, 2004, 100(4), 751-757.
99. Zhang, M.; Mukherjee, N.; Bermudez, R.S.; Latham, D.E.; Delaney, M.A.; Zietman, A.L.; Shipley, W.U.; Chakravarti, A. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate, 2005, 64(3), 293-302.
100. Xu, Y.; Zheng, S.; Chen, B.; Wen, Y.; Zhu, S. Sodium phenylbutyrate antagonizes prostate cancer through the induction of apoptosis and attenuation of cell viability and migration. Onco. Targets Ther., 2016, 9, 2825-2833.